Precision Epigenomics Selected for 2024 Flinn Foundation Bioscience Entrepreneurship Program

By: Precision Epigenomics Inc
TUCSON, Ariz. - April 2, 2024 - PRLog -- Precision Epigenomics Inc. ("Precision Epigenomics"), a molecular diagnostic company that features liquid biopsy tests, announced today that it was selected by the Flinn Foundation as an awardee of the 2024 Bioscience Entrepreneurship program. The company has developed a multi-cancer detection test called EPISEEKTM. The Flinn Foundation program will provide Precision Epigenomics with $30,000 in non-dilutive funding and a professionally developed, yearlong plan that helps advance its commercialization. Exclusive opportunities will be offered to the competitively selected startups to engage with the state's bioscience, academic, and policy leaders, including one-year memberships to Arizona's Bioscience Roadmap Steering Committee and the Arizona Bioindustry Association. In addition, the executive team of Precision Epigenomics (Mark Nelson, CEO; Richard Bernert, COO, Matt Miller, CFO, and Josh Routh, Medical Director) will be invited to meet with fellow bioscience entrepreneurs in the state.

"We are honored to be recognized by the Flinn Foundation for our innovative approach to earlier cancer detection and to have the opportunity to work with the AZ Bioscience Roadmap team. The currently recommended conventional screening methods for cancer underperform and they do not detect most cancer types that are killing people," said Mark Nelson, Ph.D., Co-Founder and Chief Executive Officer of Precision Epigenomics. "Our goal is to change the way cancers are detected."

"The experienced Arizona Biosciences mentors who are so generous with their time will make an impact refining our ongoing commercialization pathway," said Richard Bernert, M.D., COO of Precision Epigenomics. Joshua Routh, M.D., Medical Director for the group added, "We look forward to utilizing the Flinn Foundation resources so that we can begin to achieve better patient outcomes through earlier cancer detection with our EPISEEKTM assay. Earlier detection saves lives."

About Precision Epigenomics

Precision Epigenomics Inc ( is an innovative molecular diagnostic testing service focused on improving cancer patients' diagnosis, management, and treatment. The company is known for its knowledgeable staff, commitment to patient care, and absolute dedication to quality.

About Flinn Foundation

The Flinn Foundation ( is a private, nonprofit philanthropic endowment established in 1965 to improve the quality of life in Arizona to benefit future generations. The Foundation supports the advancement of biosciences in Arizona, a merit-based college scholarship program, arts and culture, and the Arizona Center for Civic Leadership.

Richard Bernert, MD, COO
Source:Precision Epigenomics Inc
Email:*** Email Verified
Location:Tucson - Arizona - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Precision Epigenomics News
Most Viewed
Daily News

Like PRLog?
Click to Share